Latest research on Atomoxetine

Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. This chemical is manufactured and marketed under the brand name Strattera; by Eli Lilly and Company and as a generic Attentin by Torrent Pharmaceuticals. There is currently no generic available within the United States due to patent restrictions. [Wikipedia]

Atomoxetine indications

The Atomoxetine study by Durell et al79 showing lower effect sizes in the middle-aged group (mean age 43.4 years) than in the younger adults may point in the same direction, suggesting that age may be a predictor of reduced efficacy of pharmacological treatment in adult ADHD. [source, 2016]
A Bayesian Monte Carlo procedure was used to compute 95% credible intervals to assess the effects of Dextroamphetamine and Atomoxetine on return of righting during continuous Sevoflurane general anesthesia, as described previously [13, 17, 20]. [source, 2015]
However, under the same experimental conditions Atomoxetine did not have a statistically significant effect on time to emergence from Propofol anesthesia. [source, 2015]
Despite their contrasting behavioral effects during general anesthesia, Atomoxetine and Dextroamphetamine surprisingly produced similar neurophysiological findings, causing a shift in EEG peak power from δ to θ. [source, 2015]
However, this effect is apparently unique to the prefrontal cortex because unlike Methylphenidate, Atomoxetine does not increase extracellular Dopamine levels in the striatum or nucleus accumbens [36]. [source, 2015]
Overall, Atomoxetine had no significant effect on impulsivity, measured by deliberation time, stop signal reaction time, and reflexion impulsivity. [source, 2015]
An observational study assessing the effect of Atomoxetine on blood pressure in neurogenic hypotension in PD patients is ongoing [488]. [source, 2015]
A Phase II randomised, double-blind, placebo-controlled study assessing the effect of Atomoxetine for the treatment of cognitive in PD is currently ongoing [490]. [source, 2015]
Additional compounds have been examined for efficacy in reducing DRD, including compounds with less direct and concentrated effects on DA availability, such as NE agonists (e.g., Atomoxetine), adrenergic agonists (e.g., Guanfacine), and multiple monoamine agonists (e.g., modafinil; Wilens, 2006). [source, 2015]
However, other studies have found Atomoxetine increased DRD in healthy rodents (Broos et al., 2012), or had no effect on DRD in healthy (Baarendse and Vanderschuren, 2012), spontaneously hypertensive (an animal model for ADHD; Turner et al., 2013), and cocaine-withdrawing rodents (Broos et al., 2014). [source, 2015]